Anti-CD261/DR4 Antibody, clone 1B7 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1B7 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects CD261/DR4. It targets an epitope within 25 amino acids from N-terminal, extracellular domain.

KLH-conjugated linear peptide corresponding to 25 amino acids from the N-terminal, extracellular domain of human CD261/DR4.

Quality Control Testing

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis (WB): A 1:10,000 dilution of this antibody detected CD261/DR4 in HeLa cell lysate.

Tested Applications

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected CD261/DR4 in human thymus tissue sections.

Flow Cytometry Analysis (FC): 0.1 µg from a representative lot detected CD261/DR4 in one million HeLa cells.

Affinity Binding Assay: A representative lot of this antibody bound CD261/DR4 peptide with at least one hundred thousand-fold (100,000X) higher than with non-specific control peptide.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected CD261/DR4 in A549 cells.

Tumor necrosis factor receptor superfamily member 10A (UniProt: O00220; also known as Death receptor 4, TNF-related apoptosis-inducing ligand receptor 1, TRAIL receptor 1, TRAIL-R1, CD261) is encoded by the TNFRSF10A (also known as APO2, DR4, TRAILR1) gene (Gene ID: 8797) in human. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1 and Fas. The ligand for this novel cell death receptor DR4 has been identified and termed TRAIL, which is a new member in TRF family. Therefore, DR4 is also called TRAIL receptor-1 (TRAIL-R1). CD261/DR4 is a single-pass type I membrane protein, which is synthesized with a signal peptide (aa 1-23) that is subsequently cleaved off to produce the mature protein that contains an extracellular domain (aa 24-239), a transmembrane domain (aa 240-262), and a cytoplasmic domain (aa 263-468). It is widely expressed with high levels observed in spleen, peripheral blood leukocytes, small intestine, and thymus. TRAIL receptors (DR4 and DR5) induce apoptosis via caspase activation. The adapter molecule FADD is reported to recruit caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation that initiates the subsequent cascade of caspases mediating apoptosis. O-GlcNAcylation of DR4 is reported to be crucial for TRAIL death signaling. CD261 is a key player in cancer biology. Both TRAIL-sensitive and TRAIL-resistant breast cancer cell lines can be efficiently killed by overexpression of the CD261/DR4. However, the extent of cell death depends on the strength of the promoter driving DR4 expression. Dysregulation of CD261-mediated apoptosis can contribute to autoimmune conditions. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Lee, H., et al. (2019). Cancer Res. 79; 2839-2852; Kazhdan, I., and Marciniak, RA (2004). Cancer Gene Ther. 11(10); 691-698).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.